Free Trial
NASDAQ:AKRO

Akero Therapeutics Q1 2024 Earnings Report

Akero Therapeutics logo
$53.60 +1.84 (+3.55%)
Closing price 04:00 PM Eastern
Extended Trading
$52.20 -1.40 (-2.60%)
As of 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Akero Therapeutics EPS Results

Actual EPS
-$0.90
Consensus EPS
-$0.90
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Akero Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Akero Therapeutics Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Friday, May 10, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Akero Therapeutics' Q2 2025 earnings is scheduled for Friday, August 8, 2025, with a conference call scheduled on Monday, August 11, 2025 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Akero Therapeutics Earnings Headlines

A new rule goes live in July — and the banks are quietly cashing in
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
See More Akero Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Akero Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Akero Therapeutics and other key companies, straight to your email.

About Akero Therapeutics

Akero Therapeutics (NASDAQ:AKRO) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapies for severe metabolic and liver diseases. The company’s core focus is nonalcoholic steatohepatitis (NASH), a progressive form of fatty liver disease with significant unmet medical need. Utilizing engineered protein technology, Akero aims to restore metabolic homeostasis through molecules that mimic natural hormones and signaling pathways.

The lead investigational product in Akero’s pipeline is efruxifermin, an analog of the hormone fibroblast growth factor 21 (FGF21), which has shown promising results in reducing liver fat content and improving key biomarkers in Phase 2 clinical studies. In addition to efruxifermin, Akero is advancing complementary programs targeting other liver-related conditions and metabolic disorders, with the goal of creating combination regimens that address both liver pathology and systemic metabolic dysfunction.

Founded in 2016 and headquartered in Cambridge, Massachusetts, Akero went public in mid-2020 and maintains clinical and research operations across North America, Europe and Asia. The company collaborates with leading academic institutions and contract research organizations to support patient recruitment and trial execution worldwide. These partnerships enable Akero to accelerate the development timeline and ensure broad access to its innovative candidates.

Under the leadership of President and Chief Executive Officer John Dieck, who brings extensive experience from prior roles at Amgen and other biotech firms, Akero’s management team combines seasoned drug-development expertise with a commitment to scientific innovation. Supported by a board of directors composed of industry veterans, the company is well positioned to advance its portfolio toward regulatory milestones and, ultimately, deliver new therapeutic options for patients with liver and metabolic diseases.

View Akero Therapeutics Profile

More Earnings Resources from MarketBeat